Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 68 clinical trials
A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments (ATEZOGIST)

This trial is a prospective, randomized (1:1 ratio), multicenter, comparative and phase II study, conducted in patients with unresectable advanced gastrointestinal stromal tumors (GIST) after

  • 0 views
  • 17 May, 2022
  • 5 locations
A Study of HQP1351 in Patients With GIST or Other Solid Tumors

This study is a Multi-center, Open-label Phase 1 Study to Determine the Recommend Phase 2 Dose (RP2D) and Evaluate PK/PD and preliminary Efficacy of HQP1351 in Patients With GIST or Other Solid Tumors.

solid tumour
solid tumor
pdgfra d842v mutation
imatinib
serum pregnancy test
  • 27 views
  • 25 Mar, 2022
  • 5 locations
Selinexor as a Single Agent and in Combination With Imatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors.

This is a single-arm, two cohort, open label phase I/II clinical trial studying the combination of oral imatinib 400 mg, once daily, and oral selinexor given once weekly (Cohort A); and single-agent oral selinexor 60 mg BIW (Cohort B). The study will consist of: Cohort A: an initial escalation phase …

imatinib 400 mg
gastrointestinal stromal tumor
medication treatment
measurable disease
blood transfusion
  • 0 views
  • 26 Jan, 2021
  • 5 locations
Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)

This is a 2 arms study concerning patients with primary GIST who followed an Imatinib adjuvant treatment for 3 years after surgery and who have a high risk of recurrence. In the first arm, patients will continue Imatinib treatment for 3 more years, allowing to determine if the continuation of …

liver metastasis
renal function
imatinib
metastasis
cancer
  • 8 views
  • 09 Aug, 2021
  • 22 locations
Phase 2 Study of Rogaratinib (BAY 1163877) in the Treatment of Patients With Sarcoma Harboring Alterations in Fibroblast Growth Factor Receptor (FGFR) 1-4 and SDH-Deficient Gastrointestinal Stromal Tumor (GIST)

gastrointestinal stromal tumor (GIST). Rogaratinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

  • 0 views
  • 18 Sep, 2022
  • 5 locations
Detective Flow Imaging Endoscopic Ultrasonography in Subepithelial Lesions

Gastrointestinal stromal tumors (GIST) are the most common malignant subepithelial lesions (SELs) found in the gastrointestinal tract. The diagnosis and differentiation of these lesions from

leiomyoma
  • 0 views
  • 11 Aug, 2022
  • 1 location
A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in Subjects With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors

This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 426 patients. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of CGT9486 to be used in subsequent parts in approximately …

tyrosine
sunitinib
measurable disease
  • 0 views
  • 19 Aug, 2022
  • 12 locations
Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot)

This study will enroll patients who have a diagnosis of locally advanced, unresectable or metastatic soft tissue or bone sarcoma (except gastrointestinal stromal tumors and Kaposi's sarcoma

measurable disease
trabectedin
angiosarcoma
liposarcoma
gemcitabine
  • 0 views
  • 26 Mar, 2022
  • 1 location
Advanced Gastrointestinal Endoscopic Imaging

To develop new methods to detect malignant and premalignant conditions of the gastrointestinal tract.

indocyanine green
fluorescence imaging
endoscopy
  • 10 views
  • 24 May, 2022
  • 1 location
Dosing of Various Multi Kinases Inhibitors Plasma Concentrations for Patients Treated for Their Advanced Digestive Cancer, With the Aim to Determine the Best Optimal Dose for Each Treatment, in the Future (TARGETMONITO)

stromal tumor (GIST), metastatic colorectal cancer (mCRC), hepatocellular carcinoma (HCC), gastroenteropancreatic neuroendocrine tumor (gepNET), or pancreatic neuroendocrine tumor (pNET)), with the aim of

  • 0 views
  • 20 Sep, 2022
  • 1 location